Sorafenib tosylateProduct ingredient for Sorafenib

Show full entry for Sorafenib
Name
Sorafenib tosylate
Drug Entry
Sorafenib

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.1 First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.3

See full entry for Sorafenib
Accession Number
DBSALT000165
Structure
MOLSDFPDBSMILESInChI
Synonyms
Sorafenib tosilate / Sorafenib tosylate
External IDs
BAY 54 9085 / BAY 54-9085 / BAY 549085 / BAY-54-9085 / BAY549085